4DMedical Ltd (AU:4DX)
ASX:4DX
Want to see AU:4DX full AI Analyst Report?
4DX Stock Chart & Stats
AU$5.84
<AU$0.01(1.02%)
At close: 4:00 PM EST
AU$5.84
<AU$0.01(1.02%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$7.55
Previous CloseN/A
Volume497.15K
Average Volume (3M)10.77M
Market Cap
AU$2.29B
Enterprise ValueAU$2.30B
Total Cash (Recent Filing)AU$56.76M
Total Debt (Recent Filing)AU$6.42M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Aug 27, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding595,097,660
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$4.97Price Target Upside-14.95% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.21
Revenue Forecast (FY)AU$9.00M
Bulls Say, Bears Say
Bulls Say
Proprietary XV Imaging Technology4DMedical's proprietary XV imaging and analytics create functional lung maps integrated into clinician workflows. As a software-driven diagnostic tool, XV can scale across hospitals, supports recurring clinical use, and builds data moats via clinical validation and installed base, creating a durable competitive advantage in respiratory imaging.
Conservative Leverage / Low DebtThe company's relatively low leverage provides financial flexibility despite operational losses. A conservative balance sheet reduces refinancing and solvency risk, enabling management to continue clinical commercialization and R&D over multiple quarters without immediate pressure to sell assets or seek urgent emergency financing.
High Gross Profit Margin On Core OfferingReported high gross margins are consistent with a software/analytics business model where incremental sales scale efficiently. If the company can stabilize sales, gross margin strength enables operating leverage to drive long-term profitability as fixed costs are amortized over higher revenue bases.
Bears Say
Declining Revenue TrendA year-over-year revenue decline signals weakening commercial traction or reimbursement adoption. Sustained top-line contraction hampers the firm's ability to achieve scale, delays operating leverage, and reduces the capacity to fund sales, training, and partnerships necessary for long-term market penetration.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows mean the business consumes cash to maintain operations and invest. This structural cash burn requires ongoing external financing or cutbacks, which can dilute shareholders or limit investment in commercialization and clinical validation over multiple quarters.
Persistent Net Losses And Negative ROEOngoing net losses and negative ROE indicate the company is not generating returns on shareholder capital. Over time this erodes equity value, constrains reinvestment capacity, and makes it harder to attract long-term institutional investors without a clear, durable path to profitability or improved unit economics.
4DMedical Ltd News
4DX FAQ
What was 4DMedical Ltd’s price range in the past 12 months?
4DMedical Ltd lowest share price was AU$0.23 and its highest was AU$7.55 in the past 12 months.
What is 4DMedical Ltd’s market cap?
4DMedical Ltd’s market cap is AU$2.29B.
When is 4DMedical Ltd’s upcoming earnings report date?
4DMedical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 85 days.
How were 4DMedical Ltd’s earnings last quarter?
4DMedical Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.259 earnings per share for the quarter, missing the consensus estimate of -AU$0.036 by -AU$0.223.
Is 4DMedical Ltd overvalued?
According to Wall Street analysts 4DMedical Ltd’s price is currently Overvalued.
Does 4DMedical Ltd pay dividends?
4DMedical Ltd does not currently pay dividends.
What is 4DMedical Ltd’s EPS estimate?
4DMedical Ltd’s EPS estimate is -0.04.
How many shares outstanding does 4DMedical Ltd have?
4DMedical Ltd has 595,097,660 shares outstanding.
What happened to 4DMedical Ltd’s price movement after its last earnings report?
4DMedical Ltd reported an EPS of -AU$0.259 in its last earnings report, missing expectations of -AU$0.036. Following the earnings report the stock price went up 7.527%.
Which hedge fund is a major shareholder of 4DMedical Ltd?
Currently, no hedge funds are holding shares in AU:4DX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4DMedical Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$4.97 (-14.95% Downside)
AU$4.97 (-14.95% Downside)
Blogger Sentiment
Bullish
AU:4DX Sentiment 93%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
205.21%
12-Months-Change
Fundamentals
Return on Equity
-890.76%
Trailing 12-Months
Asset Growth
36.79%
Trailing 12-Months
Company Description
4DMedical Ltd
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
4DX Stock 12 Month Forecast
Average Price Target
AU$4.97
▼(-14.95% Downside)
Technical Analysis
Impedimed Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
Options Prices
Currently, No data available
---